Skip to main content

Table 1 Baseline characteristic of study patients

From: Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial

Variable All (n = 30) Placebo (n = 15) Dapagliflozin (n = 15) p
Age, years 63.4 ± 6.9 61.0 ± 7.2 65.7 ± 5.9 0.057
Sex male, % 66.7 66.7 66.7 1.000
Body mass index, kg/m2 30.8 ± 5.2 32.8 ± 5.4 28.8 ± 4.3 0.032§
HbA1c, % 8.2 ± 0.8 8.2 ± 0.9 8.2 ± 0.6 0.981
Diabetes duration, years 14.1 ± 6.6 13.9 ± 5.2 14.2 ± 8.0 0.914
Hypertension, % 90.0 93.3 86.7 1.000
Smoking habit, % 16.7 20.0 13.3 1.000
Dyslipidemia, % 93.3 86.7 100 0.483
Creatinine, mg/dl 0.81 ± 0.2 0.81 ± 0.2 0.82 ± 0.2 0.921
eGFR (ml/min/1.73 m2) 90.6 ± 16.7 92.5 ± 16.9 88.7 ± 17.0 0.551
Retinopathy, % 26.7 33.3 20.0 0.682
Nephropathy, % 23.3 33.3 13.3 0.390
Neuropathy, % 3.3 6.7 0.0 1.000
Coronary artery disease, % 26.7 40.0 13.3 0.215
History of HF or systolic LV dysfunction, % 0.0 0.0 0.0 1.000
LV hypertrophy, % 46.7 53.3 40.0 0.715
Diastolic LV disfunction, % 43.3 46.7 40.0 1.000
Peripheral arterial disease, % 0.0 0.0 0.0 1.000
Cerebrovascular disease, % 56.7 53.3 60.0 1.000
Metformin, % 93.3 100 86.7 0.483
Sulphonylureas, % 20.0 20.0 20.0 1.000
DPP-4 inhibitors, % 20.0 13.3 26.7 0.651
Basal insulin, % 16.7 13.3 20.0 1.000
Basal-bolus insulin, % 36.7 46.7 26.7 0.500
ACE inhibitors/ARBs, % 83.3 86.7 80.0 1.000
Diuretics, % 33.3 26.7 40.0 0.700
Calcium channel blockers, % 30.0 33.3 26.7 1.000
Beta blocker, % 26.7 26.7 26.7 1.000
Statins, % 90.0 100.0 80.0 0.224
Anti-platelets, % 50.0 60.0 40.0 0.466
  1. Data are expressed as mean ± standard, or percentages
  2. §Not significant after correction of type I error